Molecular Vision: Jafri, Mol Vis 2018; 24:495-508. Table 1

Table 1. Effect of treatment with MgAT and TAU on NMDA-induced changes in retinal expression of NOS isoforms as determined by ELISA.

Treatment		nNOS (ng/mg protein)	iNOS (ng/mg protein)	eNOS (pg/mg protein)
PBS		0.034±0.018	0.072±0.029	5.320±0.905
NMDA		4.729±0.880***	8.039±2.125***	1.926±0.980**
Pre	MgAT	0.422±0.179*##	0.247±0.108*##$$	3.789±0.214#$
Pre	Tau	0.513±0.178***##	1.659±0.521**##	2.536±0.492
Co	MgAT	0.558±0.196*#	1.498±0.369**##	3.162±0.639*#
Co	Tau	0.441±0.065***#	2.161±0.266***##	2.869±0.650*
Post	MgAT	2.952±0.956*	1.235±0.487*#	2.819±0.298*
Post	Tau	4.467±1.439**	1.950±0.587**#	2.783±0.623*

All values are mean ± SD n=6. *p<0.05 versus PBS group; **p<0.01 versus PBS group, ***p<0.001 versus PBS group, #p<0.05 versus NMDA group, ##p<0.01 versus NMDA group, $p<0.05 corresponding MgAT versus TAU groups; $$p<0.01 corresponding MgAT versus TAU groups NMDA: N-methyl-D-aspartic acid, MgAT: Magnesium Acetlytaurate, TAU: Taurine, Pre: Treatment was given 24 h before NMDA; Co-treatment was co-administered with NMDA; Post: treatment was administered 24 h after NMDA.